Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shanghai Pharmaceutical (Group), Science And Technology Commission Collaborate On Drug Research

This article was originally published in PharmAsia News

Executive Summary

Shanghai Pharmaceutical (Group), China's largest pharmaceutical company, has signed an agreement with the Science and Technology Commission of Shanghai Municipality to promote deep integration between industry, academia and clinical research. Both parties will jointly invest and set up a research fund for the pharmaceutical group's new drug research and development, quality improvement, as well as development of new clinical applications for existing drugs. With its comprehensive coverage, SPG is leading Shanghai's latest biopharmaceutical push (PharmAsia News, Aug. 10, 2009). The company has identified 10 key products for redevelopment and plans to invest RMB 1.15 billion in new drug R&D and new technology platforms over the next three years. STCSM will initially review candidate projects and conduct post-implementation evaluations. (Click here for more - Chinese Language)
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

SC072505

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel